ADARx Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, ADARx Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
ADARx Pharmaceuticals: 4 sponsored US clinical trials, 4 recruiting.
ADARx Pharmaceuticals sponsors 4 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting. 2 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hereditary Angioedema - Type 2, with 1 trials.
Upper-quartile sponsor footprint
ADARx Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 2 |
What is open in the ADARx Pharmaceuticals pipeline
4 recruiting of 4 indexed (100% open).
Phase mix: 2 late (III/IV) vs 2 early (I/II) (balanced across stages).
Top condition: Hereditary Angioedema - Type 2 (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
ADARx Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 4 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
ADARx Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- Adcendo ApS · 100% recruiting · 3 trials
Related
What to do with this ADARx Pharmaceuticals page
4 registered trials is a research-attention snapshot, not an endorsement of ADARx Pharmaceuticals or any single study.
- 4 of ADARx Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hereditary Angioedema - Type 2 is the condition ADARx Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hereditary Angioedema - Type 2 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. ADARx Pharmaceuticals pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.